Eyes turn to US Fed call as markets ‘tolerate’ UK Budget In London, the FTSE 100 index ended up 7.96 points, or 0.1%, at 10,694.50. Evening Standard · 14h ago
GSK shares dive as weaker vaccine sales unnerve investors British pharma company one of biggest fallers on FTSE 100 despite better than expected financial results The Guardian - UK · 19h ago
GSK sees falling vaccine sales take shine off earnings The drugs giant revealed vaccine sales fell 2% to £2.6 billion in the three months to September 30 as demand waned for its shingles and RSV jabs. Evening Standard · 20h ago
'Not every decision was bad': under-fire plasma giant A healthcare giant famous for pioneering a cervical cancer vaccine is adamant that its underlying operations are strong, despite a torrid couple of years. AAP · Oct 27
Hibsago Hepatitis B Shot Kept Virus Controlled in Nearly 1 in 5 Off Treatment but Carries Boxed Warning FDA approved Hibsago for chronic hepatitis B with a boxed warning for liver reactions and low platelets. Here is who qualifies and what to monitor. Medical Daily · Oct 22
Jemperli Wins Accelerated FDA Approval for a Rectal Cancer Subtype as Most Trial Patients Avoided Surgery FDA gave Jemperli accelerated approval for dMMR rectal cancer. Most trial patients skipped surgery, but the data are interim. What patients should ask. Medical Daily · Oct 20
Roche Bets Up to $1.16 Billion on Rona's Obesity Drug That Aims to Cut Fat but Spare Muscle Roche licensed Rona's experimental ALK7 obesity drug in a deal worth up to $1.16 billion. No human data are out yet. What it means for weight loss. Medical Daily · Oct 15
Andy Burnham unveils £48m partnership in bid to ‘defeat’ dementia The Prime Minister’s father Roy died last month after suffering from Alzheimer’s. The Independent UK · Oct 9
Andy Burnham announces £48m partnership in bid to find dementia cure The Prime Minister, whose father Roy died last month after suffering from Alzheimer’s, said he wanted Britain ‘to be the country that makes the breakthrough’ The Independent UK · Oct 8
Former Sensodyne boss behind launch of new toothpaste for sensitive teeth The UK oral care market is worth more than £1 billion, according to Market Data Forecast figures. Evening Standard · Oct 7
HRSA Names 10 Drugmakers and 21 Drugs for 340B Rebate Pilot as Hospitals Weigh Options Before January Launch HRSA approved 10 drugmakers and 21 drugs, including Eliquis and Jardiance, for its 340B rebate pilot starting Jan. 1 as hospitals weigh legal options. Medical Daily · Oct 5
An Immunotherapy Drug Is Letting Some Rectal Cancer Patients Skip Surgery: An Oncologist Explains Who It Could Help Dostarlimab cleared tumors in every rectal cancer patient who completed treatment in a landmark study, and the FDA is now reviewing it for this use. But the approach works for only a small, specific group of patients, and long-term answers are still coming. Medical Daily · Sep 23
European drugmakers say they are ‘losing ground’ to US and Chinese rivals Some of continent’s biggest pharma firms write to national leaders calling for action to safeguard the sector The Guardian - UK · Sep 22
Guideline Care Cut Their Coughing in Half, and 71 Percent Still Said It Was Not Enough A McMaster cough clinic followed 100 patients through guideline-based care. Cough frequency fell by 54 percent, yet 71 percent still lacked control. Medical Daily · Sep 9
Medical Daily · Aug 27 Shingrix Recipients Were 10 Percent Less Likely to Be Diagnosed with Heart Disease Than Zostavax Recipients An Oxford-led study of more than 70,000 older adults found Shingrix recipients had 10 percent fewer heart disease diagnoses than Zostavax recipients.
Medical Daily · Aug 17 Merck Puts a Decade Timeline on the MMR Split Order as Single Disease Shots Remain Unlicensed Merck and GSK say separate measles, mumps, and rubella shots could take up to a decade to reach US pediatric offices. What families face now.
Evening Standard · Aug 14 FTSE 100 drifts lower in mixed day for Europe The index closed down 22.56 points, 0.2%, at 10,750.11.
The Economic Times · Aug 13 Trump’s vaccine overhaul could bring more shots, higher costs for US families President Donald Trump's vaccine plan faces significant financial and logistical hurdles. Drugmakers must develop new manufacturing processes and conduct extensive clinical studies. Separating vaccines could lead to more appointments and increased costs for families. Public health experts question the scientific basis for the proposed changes. States retain authority to mandate…
The Independent UK · Aug 13 Trump's vaccine plan would require millions of individual shots last used decades ago The biggest obstacles to President Donald Trump’s order on vaccines may be the logistical challenges it poses for U.S. parents, health providers and drugmakers
The Guardian - UK · Jul 28 GSK heads to Cambridge with long-awaited positive vibes Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders
Evening Standard · Jul 28 Earnings tonic boosts FTSE 100 as oil falls back Well-received earnings from Unilever, Croda and GSK spurred gains on the blue-chip FTSE 100.
The Guardian - UK · Jul 28 GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site
The Independent UK · Jul 28 Pharma giant GSK to relocate research headquarters to Cambridge in £400m move GSK is hoping all workers will relocate to either Cambridge or Ware
Evening Standard · Jul 28 GSK to shut Stevenage R&D hub under plans to open new site in Cambridge The move will impact around 1,800 staff currently based in Stevenage.